Published in Antimicrob Agents Chemother on November 01, 1990
Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother (1997) 1.09
In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei. Antimicrob Agents Chemother (2001) 0.88
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med (1983) 5.41
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med (1982) 4.04
LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed (1983) 4.02
Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother (1980) 3.60
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med (1989) 3.16
Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics (1983) 3.00
Ribavirin small-particle aerosol treatment of influenza. Lancet (1981) 2.91
Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol (1988) 2.84
Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med (1969) 2.61
Treatment of influenza. The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak. Am J Med Sci (1969) 2.54
Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 2.53
Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA (1981) 2.50
Maintenance of viability and comparison of identification methods for influenza and other respiratory viruses of humans. J Clin Microbiol (1977) 1.73
Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother (1980) 1.61
Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice. J Infect Dis (1976) 1.56
Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother (1984) 1.43
Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother (1985) 1.29
Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother (1986) 1.13
Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis (1980) 1.08
Combined action of ribovirin and rimantadine in experimental myxovirus infection. Experientia (1977) 1.05
Estimating the dosage of ribavirin aerosol according to age and other variables. J Infect Dis (1988) 1.04
Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis (1981) 1.02
A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Virol (1987) 0.98
Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother (1984) 0.95
Amantadine aerosol in humans. Antimicrob Agents Chemother (1979) 0.92
Quantitative determination of rimantadine in human plasma and urine by GC-MS. Biomed Environ Mass Spectrom (1987) 0.87
The effects of peroral or local aerosol administration of 1-aminoadamantane hydrochloride (amantadine hydrochloride) on influenza infections of the ferret. J Antimicrob Chemother (1977) 0.84
Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium. J Antimicrob Chemother (1983) 0.80
Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res (1982) 0.80
Anti-influenza A virus activity of amantadine hydrochloride and rimantadine hydrochloride in ferret tracheal ciliated epithelium. Antimicrob Agents Chemother (1982) 0.77
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
Activation of transcription of hut DNA by glutamine synthetase. Proc Natl Acad Sci U S A (1974) 5.61
A new glnA-linked regulatory gene for glutamine synthetase in Escherichia coli. Proc Natl Acad Sci U S A (1979) 5.28
Regulation of the assimilation of nitrogen compounds. Annu Rev Biochem (1978) 4.36
A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans. J Immunol (1970) 4.12
Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med (1977) 3.97
Interpandemic influenza in the Houston area, 1974-76. N Engl J Med (1978) 3.92
Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother (1974) 3.86
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA (2000) 3.50
Immunity to influenza in man. Annu Rev Microbiol (1983) 3.22
Regulation of expression from the glnA promoter of Escherichia coli in the absence of glutamine synthetase. Proc Natl Acad Sci U S A (1980) 3.19
Regulation of glutamine synthetase formation in Escherichia coli: characterization of mutants lacking the uridylyltransferase. J Bacteriol (1978) 3.07
Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol (1979) 3.05
Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics (1983) 3.00
Ribavirin small-particle aerosol treatment of influenza. Lancet (1981) 2.91
Transient repression of the lac operon. J Bacteriol (1967) 2.79
Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis (1997) 2.78
Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis (1974) 2.66
Assessment of experimental and natural viral aerosols. Bacteriol Rev (1966) 2.64
Comparison of rapid diagnostic techniques for respiratory syncytial and influenza A virus respiratory infections in young children. J Clin Microbiol (1993) 2.50
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. Bacteriol Rev (1966) 2.41
Gene organization and regulation in the qa (quinic acid) gene cluster of Neurospora crassa. Microbiol Rev (1985) 2.33
Varicella in children with cancer: Seventy-seven cases. Pediatrics (1975) 2.29
Fine-structure deletion map and complementation analysis of the glnA-glnL-glnG region in Escherichia coli. J Bacteriol (1982) 2.28
Effects of low- and high-passage influenza virus infection in normal and nude mice. Infect Immun (1977) 2.24
Sporadic occurrence of zoonotic swine influenza virus infections. J Clin Microbiol (1984) 2.24
Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis (1971) 2.13
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
The role of nasal secretion and serum antibody in the rhinovirus common cold. Am J Epidemiol (1966) 2.11
Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci (1971) 2.08
Pre-reconstruction tattooing eliminates the need for skin grafting in nipple areolar reconstruction. Plast Reconstr Surg (1993) 2.06
Academic anaesthetists--an endangered species? Anaesthesia (1997) 2.04
Protein composition of nasal secretion during respiratory virus infection. Proc Soc Exp Biol Med (1965) 2.03
Physiological basis of transient repression of catabolic enzymes in Escherichia coli. J Bacteriol (1970) 2.00
The products of glnL and glnG are bifunctional regulatory proteins. Mol Gen Genet (1982) 2.00
Ribavirin aerosol treatment of influenza B virus infection. JAMA (1983) 1.99
Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr (1978) 1.99
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Deletion mapping of the polA-metB region of the Escherichia coli chromosome. J Bacteriol (1979) 1.97
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine (1997) 1.95
Regulation of glnA messinger ribonucleic acid synthesis in Klebsiella aerogenes. J Bacteriol (1977) 1.95
Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr (1992) 1.94
Clonidine--a horse or an ass? Anaesthesia (1991) 1.92
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci (1967) 1.87
Acute transverse myelitis: incidence and etiologic considerations. Neurology (1981) 1.84
Studies of morphology and immunofluorescence of Pneumocystis carinii. Proc Soc Exp Biol Med (1972) 1.82
China's 50% caesarean delivery rate: is it too high? BJOG (2014) 1.78
Catabolite repression gene of Escherichia coli. J Bacteriol (1969) 1.78
Amantadine small-particle aerosol: generation and delivery to man. Proc Soc Exp Biol Med (1979) 1.76
Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. Am J Epidemiol (1980) 1.74
The influenza herald wave. Am J Epidemiol (1982) 1.74
Maintenance of viability and comparison of identification methods for influenza and other respiratory viruses of humans. J Clin Microbiol (1977) 1.73
Antibody to Mycoplasma pneumoniae in nasal secretions and sputa of experimentally infected human volunteers. Infect Immun (1973) 1.72
Immunofluorescent diagnosis of acute viral infection. South Med J (1975) 1.71
Bacterial spinal epidural abscess. Review of 43 cases and literature survey. Medicine (Baltimore) (1992) 1.71
Effects of tetracycline on leukotaxis. J Infect Dis (1974) 1.69
Dual respiratory virus infections. Clin Infect Dis (1997) 1.67
Spectrum of clinical illness in hospitalized patients with "common cold" virus infections. Clin Infect Dis (2000) 1.66
Influenza: its control in persons and populations. J Infect Dis (1986) 1.65
Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med (1988) 1.65
Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. J Infect Dis (1976) 1.64
Predicting risk of complications with gynecologic laparoscopic surgery. Obstet Gynecol (1998) 1.62
Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother (1980) 1.61
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol (1994) 1.61
Rhinovirus neutralizing antibody in tears, parotid saliva, nasal secretions and serum. J Immunol (1967) 1.59
Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child (1990) 1.56
Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med (2001) 1.55
Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med (1998) 1.55
Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest (1995) 1.55
The effects of influenza on host defenses. J Infect Dis (1981) 1.54
Molecular basis of transient repression of beta-galactosidase in Escherichia coli. J Bacteriol (1969) 1.54
Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) (1983) 1.50
Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr (1973) 1.49
Right ventricular function and exercise performance late after primary repair of tetralogy of Fallot with the transannular patch in infancy. Am J Cardiol (1998) 1.49
Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man. J Immunol (1970) 1.49
Medication errors in neonatal and paediatric intensive-care units. Lancet (1989) 1.48
Pneumatosis intestinalis in two infants with rotavirus gastroenteritis. Pediatr Radiol (1991) 1.47
Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis (1983) 1.46
The regulation of folate and methionine metabolism. Biochem J (1976) 1.46
Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res (1996) 1.45
Infection with influenza A/Victoria virus in Houston families, 1976. J Hyg (Lond) (1981) 1.44
Mutations that create new promoters suppress the sigma 54 dependence of glnA transcription in Escherichia coli. J Bacteriol (1987) 1.44
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol (1984) 1.44
Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother (1984) 1.43
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43